Apolipoprotein E polymorphism and hyperlipoproteinemia in obesity.

Area of Science:

• Genetics
• Metabolic Disorders
• Cardiovascular Disease

Background:

• Obesity is a significant risk factor for cardiovascular disease.
• Apolipoprotein E (apo E) polymorphism is implicated in lipid metabolism.
• The specific role of apo E variants in obesity-related hyperlipoproteinemia (HLP) requires further elucidation.

Purpose of the Study:

• To investigate the association between apo E polymorphism and plasma lipid profiles.
• To determine the frequency of HLP in obese individuals based on apo E genotype.
• To understand the link between apo E variants, HLP, and obesity.

Main Methods:

• Study included 87 obese subjects and 132 nonobese controls.
• Apolipoprotein E allele and phenotype frequencies were analyzed.
• Plasma lipid profiles, including triglycerides and HDL cholesterol, were measured.
• Frequency of hyperlipoproteinemia was assessed across different apo E phenotypes.

Main Results:

• No significant difference in apo E allele/phenotype frequencies between obese and nonobese groups.
• HLP frequency was 100% in obese subjects with apo E2 and/or E4, versus 47.3% in those with apo E3/3.
• Obese individuals with apo E2 showed increased triglycerides and apo E, and decreased HDL cholesterol.
• Obese individuals with apo E4 exhibited elevated triglycerides, total cholesterol, and apo E.

Conclusions:

• Obese subjects with apo E2 and/or E4 are more prone to HLP than those with apo E3/3.
• Apo E2 and E4 variants are closely associated with HLP in the context of obesity.
• These apo E variants may represent a key factor connecting obesity and cardiovascular disease risk.